PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

被引：0

作者：

Abou-Alfa, G. ^{[1
]}

Borbath, I. ^{[2
]}

Goyal, L. ^{[3
]}

Lamarca, A. ^{[4
]}

Macarulla, T. ^{[5
]}

Oh, D. ^{[6
]}

Roychowdhury, S. ^{[7
]}

Sadeghi, S. ^{[8
]}

Shroff, R. ^{[9
]}

Soto, J. ^{[10
]}

Pedrioli, G. ^{[11
]}

Fumagalli, L. ^{[11
]}

Dambkowski, C. ^{[10
]}

Javle, M. ^{[12
]}

机构：

[1] Cornell Univ, Mem Sloan Kettering Canc Ctr, Weill Med Coll, New York, NY 10021 USA

[2] Clin Univ St Luc, Brussels, Belgium

[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[4] Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England

[5] Hosp Valle De Hebron, Barcelona, Spain

[6] Seoul Natl Univ, Coll Med, Seoul, South Korea

[7] Ohio State Comprehens Canc Ctr, Columbus, OH USA

[8] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA

[9] Univ Arizona, Ctr Canc, Tucson, AZ USA

[10] QED Therapeut Inc, San Francisco, CA USA

[11] Helsinn Healthcare SA, Lugano, Switzerland

[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.04.107

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-16

引用

页码：S251 / S252

页数：2

共 50 条

[41] A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.
Ikeda, Masafumi
Ueno, Makoto
Morizane, Chigusa
Kobayashi, Satoshi
Ohno, Izumi
Kondo, Shunsuke
Okano, Naohiro
Kimura, Keisuke
Asada, Suguru
Namba, Yoshinobu
Okusaka, Takuji
Furuse, Junji
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[42] Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial (vol 388, pg 1883, 2016)
Zhang, L.
Huang, Y.
Hong, S.
LANCET, 2016, 388 (10054): : 1882 - 1882
[43] Comparing the outcome of doublet therapy (gemcitabine and cisplatin) with triplet therapy (gemcitabine, cisplatin and nab paclitaxel) in locally advanced or metastatic gall bladder carcinoma patients: An open-label randomized control trial
Khatri, Chandrani
Das, Pratap K.
Patowary, Jayanta
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[44] Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix
Duenas-Gonzalez, Alfonso
Zarba, Juan J.
Patel, Firuza
Alcedo, Juan C.
Beslija, Semir
Casanova, Luis
Pattaranutaporn, Pittayapoom
Hameed, Shahid
Blair, Julie M.
Barraclough, Helen
Orlando, Mauro
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (13) : 1678 - 1685
[45] Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC
Michael, Michael
White, Shane C.
Abdi, Ehtesham
Nott, Louise
Clingan, Phillip
Zimet, Allan
Button, Peter
Gregory, Daniel
Solomon, Benjamin
Dobrovic, Alexander
Do, Hongdo
Clarke, Stephen
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (01) : 4 - 14
[46] Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial
Ramaswamy, Anant
Bhargava, Prabhat
Srinivas, Sujay
Kapoor, Akhil
Mishra, Bal Krishna
Gupta, Anuj
Mandavkar, Sarika
Kannan, Sadhana
Chaugule, Deepali
Patil, Rajshree
Parulekar, Manali
Nashikkar, Chaitali
Ankathi, Suman Kumar
Kaushal, Rajiv Kumar
Naughane, Deepali
Daddi, Anuprita
Mer, Neha
Shetty, Nitin
Ostwal, Vikas
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (27)
[47] Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial
Jang, Jin-Young
Han, Youngmin
Lee, Hongeun
Kim, Sun-Whe
Kwon, Wooil
Lee, Kyung-Hun
Oh, Do-Youn
Chie, Eui Kyu
Lee, Jeong Min
Heo, Jin Seok
Park, Joon Oh
Lim, Do Hoon
Kim, Seong Hyun
Park, Sang Jae
Lee, Woo Jin
Koh, Young Hwan
Park, Joon Seong
Yoon, Dong Sup
Lee, Lk Jae
Choi, Seong Ho
ANNALS OF SURGERY, 2018, 268 (02) : 215 - 222
[48] Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
Fanucci, Kristina A.
Pilat, Mary Jo
Shyr, Derek
Shyr, Yu
Boerner, Scott A.
Durecki, Diane
Noonan, Anne
Abramson, Vandana
Santa-Maria, Cesar
Han, Hyo
Nanda, Rita
Dees, Elizabeth Claire
Park, Haeseong
Buys, Saundra
Peswani, Namrata
Chew, Helen
Assad, Hadeel
Wulf, Gerburg
Richardson, Angelique
Trivedi, Meghna S.
Brufsky, Adam
Abbruzzese, James
Afghahi, Anosheh
Sharon, Elad
Schalper, Kurt
LoRusso, Patricia
CANCER RESEARCH, 2023, 83 (08)
[49] Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
Ahn, Myung-Ju
Cho, Byoung Chul
Ou, Xiaoling
Walding, Andrew
Dymond, Angela W.
Ren, Song
Cantarini, Mireille
Janne, Pasi A.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (05) : 718 - 723
[50] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Lan, Chunyan
Shen, Jingxian
Wang, Yin
Li, Jundong
Liu, Zhimin
He, Mian
Cao, Xinping
Ling, Jiayu
Huang, Jiaming
Zheng, Min
Zou, Guorong
Yan, Haowen
Liu, Qing
Yang, Fan
Wei, Wei
Deng, Yanhong
Xiong, Ying
Huang, Xin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)

← 1 2 3 4 5 →